BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22326625)

  • 21. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells.
    Leroux ME; Auzenne E; Evans R; Hail N; Spohn W; Ghosh SC; Farquhar D; McDonnell T; Klostergaard J
    Prostate; 2007 Nov; 67(15):1699-717. PubMed ID: 17879964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease.
    Gangoiti P; Camacho L; Arana L; Ouro A; Granado MH; Brizuela L; Casas J; Fabriás G; Abad JL; Delgado A; Gómez-Muñoz A
    Prog Lipid Res; 2010 Oct; 49(4):316-34. PubMed ID: 20193711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.
    Pchejetski D; Doumerc N; Golzio M; Naymark M; Teissié J; Kohama T; Waxman J; Malavaud B; Cuvillier O
    Mol Cancer Ther; 2008 Jul; 7(7):1836-45. PubMed ID: 18644996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical methods for quantifying sphingolipids: ceramide, sphingosine, sphingosine kinase-1 activity, and sphingosine-1-phosphate.
    Brizuela L; Cuvillier O
    Methods Mol Biol; 2012; 874():1-20. PubMed ID: 22528435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells.
    Minelli A; Bellezza I; Tucci A; Conte C; Bracarda S; Culig Z
    Prostate; 2008 Mar; 68(4):360-72. PubMed ID: 18189232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells.
    De Luca T; Morré DM; Morré DJ
    J Cell Biochem; 2010 Aug; 110(6):1504-11. PubMed ID: 20518072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.
    Sauer L; Nunes J; Salunkhe V; Skalska L; Kohama T; Cuvillier O; Waxman J; Pchejetski D
    Int J Cancer; 2009 Dec; 125(11):2728-36. PubMed ID: 19521959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells.
    Olea-Herrero N; Vara D; Malagarie-Cazenave S; Díaz-Laviada I
    J Immunotoxicol; 2009 Dec; 6(4):249-56. PubMed ID: 19908944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia.
    Itoh M; Kitano T; Watanabe M; Kondo T; Yabu T; Taguchi Y; Iwai K; Tashima M; Uchiyama T; Okazaki T
    Clin Cancer Res; 2003 Jan; 9(1):415-23. PubMed ID: 12538495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells.
    Holman DH; Turner LS; El-Zawahry A; Elojeimy S; Liu X; Bielawski J; Szulc ZM; Norris K; Zeidan YH; Hannun YA; Bielawska A; Norris JS
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):231-42. PubMed ID: 17429631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sphingolipids in macroautophagy.
    Lavieu G; Scarlatti F; Sala G; Carpentier S; Levade T; Ghidoni R; Botti J; Codogno P
    Methods Mol Biol; 2008; 445():159-73. PubMed ID: 18425450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate.
    Cuvillier O; Pirianov G; Kleuser B; Vanek PG; Coso OA; Gutkind S; Spiegel S
    Nature; 1996 Jun; 381(6585):800-3. PubMed ID: 8657285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of ceramide on apoptosis of human colon cancer HT-29 cells].
    Zhang XF; Li BX; Ren R
    Wei Sheng Yan Jiu; 2006 Sep; 35(5):537-40. PubMed ID: 17086696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sphingosine Kinase 2 and Ceramide Transport as Key Targets of the Natural Flavonoid Luteolin to Induce Apoptosis in Colon Cancer Cells.
    Abdel Hadi L; Di Vito C; Marfia G; Ferraretto A; Tringali C; Viani P; Riboni L
    PLoS One; 2015; 10(11):e0143384. PubMed ID: 26580959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
    Batra S; Reynolds CP; Maurer BJ
    Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b.
    Lim KG; Tonelli F; Berdyshev E; Gorshkova I; Leclercq T; Pitson SM; Bittman R; Pyne S; Pyne NJ
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1457-64. PubMed ID: 22634604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
    Forde JC; Perry AS; Brennan K; Martin LM; Lawler MP; Lynch TH; Hollywood D; Marignol L
    Urol Oncol; 2012; 30(6):912-9. PubMed ID: 21176881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1.
    Min J; Mesika A; Sivaguru M; Van Veldhoven PP; Alexander H; Futerman AH; Alexander S
    Mol Cancer Res; 2007 Aug; 5(8):801-12. PubMed ID: 17699106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.